Strides Pharma Science Ltd (STAR) Q2FY26 Concall Summary - Sep-2025 Qtr
Performance Overview
- The company reported a strong Q2 FY26, demonstrating consistent execution and sustainable growth, which has created significant operating leverage.
- A modest 4.6% year-on-year revenue growth translated into a substantial 25.4% increase in EBITDA and an 84% rise in operational PAT, highlighting the multiplier effect of operational efficiency.
- The US business maintained a steady performance despite intense competition, while the 'Rest of the World' markets (Other Regulated and Growth Markets) emerged as a key growth driver, expanding by 14% year-on-year.
- The company has successfully established a new base for its 'Rest of the World' markets, which are now expected to be a significant source of new revenue, with a long-term goal of mirroring the US market's scale within three years.
- Strong operational cash flow generation of INR 394 crores in H1 enabled a free cash flow of INR 73 crores, which was utilized for debt reduction, improving the net debt to EBITDA ratio to 1.65x.
Financial Metrics
Log in to Stocksigma to read the Financial Metrics section of this summary.
Operating Performance / Business Segments
Log in to Stocksigma to read the Operating Performance / Business Segments section of this summary.
Key Discussions & Insights
Log in to Stocksigma to read the Key Discussions & Insights section of this summary.
Outlook and Guidance
Log in to Stocksigma to read the Outlook and Guidance section of this summary.
Challenges / Concerns
Log in to Stocksigma to read the Challenges / Concerns section of this summary.
Industry / Competitive Landscape
Log in to Stocksigma to read the Industry / Competitive Landscape section of this summary.
Overall Summary
Log in to Stocksigma to read the Overall Summary section of this summary.